PEDIARIX
The FDA has provided an updated indication for PEDIARIX, a combination vaccine for diphtheria, tetanus, pertussis, hepatitis B, and poliomyelitis. It is approved as a three-dose series specifically for infants born to hepatitis B surface antigen (HBsAg)-negative mothers.
This affects the manufacturer of PEDIARIX, healthcare providers administering pediatric vaccines, and regulatory professionals managing multi-antigen vaccine labeling.
The specificity regarding maternal HBsAg status is a critical limiting factor for the indicated use of this 3-dose series. This suggests that regulatory and clinical compliance teams must ensure that the product is not used as a substitute in cases where maternal HBsAg status is positive or unknown, which could impact immunization strategies for hepatitis B.
Regulatory departments should ensure all labeling and physician communications accurately reflect the specific 3-dose series indication and the maternal HBsAg-negative requirement. Quality and clinical teams should verify that administration protocols align with these specific patient population constraints.
indicated for active immunization against diphtheria, tetanus, pertussis, infection caused by all known subtypes of hepatitis B virus, and poliomyelitis. PEDIARIX is approved for use as a 3-dose series in infants born of hepatitis B surface antigen (HBsAg)-negative mothers. <br> PEDIARIX may be given as
Open in openFDA / FDA.gov